



STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.
WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

1643
HYG
09-18-98

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
MICHAEL Q. LEE

JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
STEVEN R. LUDWIG
MICHAEL V. MESSINGER
JUDITH U. KIM*
KEITH KIND
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
BARBARA A. PARVIS
MICHAEL A. RAHMAN*

STEPHEN G. WHITESIDE*
NOEL B. WHITLEY*
JEFFREY T. HELVEY*
RICHARD A. DUNNING, JR.
KIMBERLIN M. TOOHEY
RALPH P. ALBRECHT
HEIDI L. KRAUS*
JEFFREY R. KURIN*
CARL B. MASSEY, JR.*
RAYMOND MILLIEN*
PATRICK D. O'BRIEN*
BRIAN S. ROSENBLUM*

DONALD J. FEATHERSTONE**
LAWRENCE B. BUGAISKY**
KAREN R. MARKOWICZ**
GRANT E. REED**
VICTOR E. JOHNSON**
SERGE SIRA**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

WRITER'S DIRECT NUMBER:

INTERNET ADDRESS:

August 11, 1998

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
AUG 12 1998
INVENTOR SERVICE CENTER

Re: U.S. Utility Patent Application
Appl. No. 09/028,514; Filed: February 23, 1998
For: **Serum-Free Mammalian Cell Culture Supplement,
and Uses Thereof**
Inventors: Gorfien *et al.*
Our Ref: 0942.4110002/RWE/GER

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449, ten (10) pages, listing sixty-two (62) documents;
3. One copy of each of the sixty-two (62) listed documents; and
4. Return postcard.

Assistant Commissioner for Patents

August 11, 1998


Page 2

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Grant E. Reed". The signature is fluid and cursive, with the first name "Grant" being more prominent than the last name "Reed".

Grant E. Reed
Agent for Applicants
Registration No. 41,264

Applicant: Gorfien et al.

Due Date: n/a

Art Unit: 1643

Examiner: To Be Assigned

Docket: 0942.4110002

Atty: RWE/GER

Application No.: 09/028,514

Filed: February 23, 1998

For: Serum-Free Mammalian Cell Culture Medium, and Uses Thereof

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. PTO Cover Letter (in duplicate)
2. Information Disclosure Statement;
3. Form PTO-1449, ten (10) pages, listing sixty-two (62) documents;
4. One copy of each of the sixty-two (62) listed documents; and
5. Return postcard.

PLEASE DATE-STAMP AND RETURN TO OUR COURIER



#4/94/
09/18-98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gorfien *et al.*

Appl. No. 09/028,514

Filed: February 23, 1998

For: **Serum-Free Mammalian Cell
Culture Supplement, and Uses
Thereof**



Art Unit: 1643

Examiner: To Be Assigned

Atty. Docket: 0942.4110002/RWE/GER

Information Disclosure Statement

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each listed document is provided.

Document AM1 is in a foreign language. Document AM1 appears to disclose the use of a polycationic and/or a polyanionic polymer (e.g., sulfated dextran) in a culture medium that does not contain von Willebrand factor, and that is suitable for the production of factor VIII, or an analog of factor VIII.

Document AP1 is in a foreign language. An unverified English language translation of document AP1 is provided as document AT10.

The Examiner is also referred to the following list of related, co-pending patent applications:

Appl. No. 08/781,772, filed January 10, 1997;

Appl. No. 08/792,299 filed January 31, 1997;

Appl. No. 08/948,053, filed October 9, 1997;

Appl. No. 08/949,142, filed October 10, 1997;

RECEIVED

AUG 12 1998

MAIL ROOM
SERVICE CENTER

Appl. No. 09/023,790, filed February 13, 1998; and

Appl. No. 09/070,807, filed May 1, 1998.

The identification of these U.S. patent applications is not to be construed as a waiver of secrecy as to these applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.


This information disclosure statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449 and indicate in the official file wrapper of this patent application that the documents

have been considered. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Grant E. Reed
Agent for Applicants
Registration No. 41,264

Date: August 11, 1998

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

4110002.IDS